Thu, Sep 18, 2014, 2:31 PM EDT - U.S. Markets close in 1 hr 29 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Apr 25, 2013 5:10 PM Flag

    Interesting side note on Ponatinib in MTC...

    $$$$
    If you go to clinicaltrialsdotgov and use "cabozantinib" as your search query...which is what I do.
    You will find a 44th trial has been added - Ponatinib in Advanced MTC.
    An NCI-sponsored P2 that mentions both Cabo & Vandetanib as comparators.
    Not yet recruiting. It does pay to watch what all the competition is doing.
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • MTC is a RET driven cancer and Ponatinib has an even lower IC50 number for RET than Cabo; the rationale is there but the market is small and there might be confounding factors other than RET as well.

      It's also interesting that the circumstances behind the birth of the two drugs is so different: Ponatinib was designed from the ground up with a warhead like protrusion in its molecular structure for better receptor inhibition whereas Cabo was found through systematically testing thousands of random compounds.

 
EXEL
1.724+0.024(+1.41%)2:31 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.